Neovacs
Biotech firm developing immunotherapies and investing in BioTech and MedTech.
ALNEV | Euronext Growth
Overview
Corporate Details
- ISIN(s):
- FR0004032746 (+4 more)
- LEI:
- 9695001J9GMM5XYK6482
- Country:
- France
- Address:
- 14 RUE DE LA REPUBLIQUE, 92150 SURESNES
- Website:
- https://www.neovacs.com/en/
Description
Neovacs is a biotechnology company with two main activities: research and development, and investment. The company's R&D focuses on its proprietary Kinoid technology platform, an active immunotherapy approach for treating autoimmune diseases and allergies. This technology develops therapeutic vaccines designed to stimulate the patient's immune system to regulate the overproduction of harmful cytokines. Key indications for its Kinoid products include lupus. In addition to its internal development, Neovacs invests in high-potential BioTech and MedTech companies, leveraging its experienced team to evaluate and support innovative products and medical devices.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-06-28 20:00 |
Succès de l'émission d'obligations remboursables en actions assorties de bons d…
|
French | 255.8 KB | ||
| 2023-06-23 08:00 |
Déjà près de 1,8 MEUR de demandes de souscription à l'émission d'obligations re…
|
French | 260.0 KB | ||
| 2023-06-19 08:00 |
Signature de la convention de fiducie destinée à l'equitization des obligations…
|
French | 266.1 KB | ||
| 2023-06-06 08:05 |
Néovacs dévoile les avancées de son portefeuille de participations et la créati…
|
French | 220.9 KB | ||
| 2023-06-06 08:00 |
Lancement d'une offre au public d'obligations remboursables en actions assortie…
|
French | 506.1 KB | ||
| 2023-06-02 08:00 |
Premier jour de cotation des actions Néovacs regroupées (ALNEV / FR001400HDX0)
|
French | 157.4 KB | ||
| 2023-05-29 18:00 |
Assemblée générale mixte le 30 juin 2023
|
French | 156.3 KB | ||
| 2023-05-02 08:00 |
Résultats annuels 2022
|
French | 230.7 KB | ||
| 2023-04-18 18:00 |
Levée de fonds de 0,5 MEUR
|
French | 236.1 KB | ||
| 2023-04-18 18:00 |
Information relative au nombre total de droits de vote et d'actions composant l…
|
French | 152.2 KB | ||
| 2023-04-14 08:00 |
Regroupement des actions Néovacs, ajustement de la valeur nominale et suspensio…
|
French | 168.7 KB | ||
| 2023-04-13 08:00 |
Nouvelles avancées dans le traitement du lupus
|
French | 182.1 KB | ||
| 2023-03-07 18:00 |
Information relative au nombre total de droits de vote et d'actions composant l…
|
French | 152.8 KB | ||
| 2023-03-06 08:00 |
Nouvelle publication scientifique dans la revue Allergy
|
French | 248.5 KB | ||
| 2023-03-02 18:00 |
Levée de fonds de 1 MEUR
|
French | 234.6 KB |
Automate Your Workflow. Get a real-time feed of all Neovacs filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Neovacs
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Neovacs via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
